Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers.
$1.71-14.50%
报价 2026-11-13
市值
$64.4M
EV
$-35.6M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -64.2%
$1.53$4.78
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ADAGAdagene Inc. | $64.4M | -14.5% | – | 94.2% | – | – | – | |
| GOSSGossamer Bio, Inc. | $67.1M | -2.4% | -57.8% | 99.6% | – | – | – | |
| CSBRChampions Oncology, Inc. | $65.5M | +1.2% | +11.6% | 43.4% | – | – | – | |
| MISTMilestone Pharmaceuticals Inc. | $64.7M | -20.6% | – | 94.6% | – | – | – | |
| CGTXCognition Therapeutics, Inc. | $64.6M | +0.5% | +14.4% | 0% | – | – | – | |
| FBIOFortress Biotech, Inc. | $62.7M | -5.5% | +31.4% | 64.5% | 1.0x | – | 0.8x | |
| CINGCingulate Inc. | $62.5M | -4.2% | -87.1% | 0% | – | – | – | |
| ACRVAcrivon Therapeutics, Inc. Common Stock | $62.1M | -0.7% | +1400.0% | 0% | – | – | – | |
| MAIAMAIA Biotechnology, Inc. | $61.8M | -1.0% | – | – | – | – | – | |
| 同行中位数 | – | – | +13.0% | 43.4% | 1.0x | – | 0.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。